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Abstract
Background: Huntington’s disease (HD) is a devastating brain disorder with no effective treatment or cure available.
The scarcity of brain tissue makes it hard to study changes in the brain and impossible to perform longitudinal studies.
However, peripheral pathology in HD suggests that it is possible to study the disease using peripheral tissue as a
monitoring tool for disease progression and/or efficacy of novel therapies. In this study, we investigated if blood can
be used to monitor disease severity and progression in brain. Since previous attempts using only gene expression
proved unsuccessful, we compared blood and brain Huntington’s disease signatures in a functional context.
Methods: Microarray HD gene expression profiles from three brain regions were compared to the transcriptome of
HD blood generated by next generation sequencing. The comparison was performed with a combination of
weighted gene co-expression network analysis and literature based functional analysis (Concept Profile Analysis).
Uniquely, our comparison of blood and brain datasets was not based on (the very limited) gene overlap but on the
similarity between the gene annotations in four different semantic categories: “biological process”, “cellular
component”, “molecular function” and “disease or syndrome”.
Results: We identified signatures in HD blood reflecting a broad pathophysiological spectrum, including alterations
in the immune response, sphingolipid biosynthetic processes, lipid transport, cell signaling, protein modification,
spliceosome, RNA splicing, vesicle transport, cell signaling and synaptic transmission. Part of this spectrum was
reminiscent of the brain pathology. The HD signatures in caudate nucleus and BA4 exhibited the highest similarity
with blood, irrespective of the category of semantic annotations used. BA9 exhibited an intermediate similarity, while
cerebellum had the least similarity. We present two signatures that were shared between blood and brain: immune
response and spinocerebellar ataxias.
Conclusions: Our results demonstrate that HD blood exhibits dysregulation that is similar to brain at a functional
level, but not necessarily at the level of individual genes. We report two common signatures that can be used to
monitor the pathology in brain of HD patients in a non-invasive manner. Our results are an exemplar of how signals in
blood data can be used to represent brain disorders. Our methodology can be used to study disease specific
signatures in diseases where heterogeneous tissues are involved in the pathology.
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Background
Huntington’s disease (HD) is a devastating disease that is
inherited in an autosomal dominant manner. The genetic
cause of the disease is a CAG repeat expansion in the
coding region of the huntingtin gene (HTT). This is trans-
lated to an expanded stretch of glutamine amino acids in
the huntingtin protein (HTT) and this mutant protein is
the main cause of neuropathology in HD. While extensive
research has been done since 1993, when the genetic cause
of the disease was discovered [1], there is still no cure for
this disease nor an effective treatment.
Clinical and imaging biomarkers have been developed
that measure the disease state and progression [2]. Nev-
ertheless, these biomarkers can be expensive and often
cannot monitor changes before onset of clinical symp-
toms. To develop an intervention that starts before disease
onset it is important to have biomarkers that can accu-
rately measure changes between controls and HD patients
before symptoms first arise. To date, promising clinical tri-
als targeting the mutant protein are under development
and robust as well as reliable biomarkers are essential
to advance these novel therapeutic strategies into the
clinic.
Although the main pathology of HD is found in the
brain, human brain tissue cannot be used to measure
molecular biomarkers to monitor disease state and pro-
gression in living patients. However, due to the ubiquitous
expression of the mutant protein, the HD phenotype is
not limited to the brain. Symptoms such as weight loss,
skeletal muscle wasting and cardiac failure, point out an
altogether complex pathology that involves many tissues
[3, 4]. This opens the opportunity to investigate HD
related pathology in more accessible tissues that can be
obtained in a non-invasive manner. Transcriptional dys-
regulation is a prominent feature of the disease. Expres-
sion profiling studies in brain have shown that in the
caudate nucleus 21 % (9763) of the probe sets demon-
strated significant differential expression [5]. Investigating
gene expression changes in peripheral tissue can provide
new insights that can lead to the development of new
therapies and biomarkers to monitor disease progression.
Using post mortem brain tissue can however introduce
biases when studying disease mechanisms due to non-
disease specific effects of post mortem interval and spe-
cific agonal conditions such as coma, hypoxia and seizures
[6]. Several studies have focused on the analysis of blood
using microarray technology, to study the pathology in
HD. However, HD-specific gene expression changes are
less pronounced in blood and it has proven difficult to val-
idate them across studies [7, 8]. For example, Borovecki
et al. analyzed global changes in mRNA expression in the
blood samples of HD patients, compared with controls
and identified a set of 12 genes that were able to clearly
distinguish controls and patients with HD [9]. Although
this work was highly promising, to this date their results
have proven difficult to replicate.
More promising biomarkers emerged with the advances
in next-generation sequencing. Mastrokolias et al. iden-
tified a HD signature that included 40 genes that were
previously reported in at least one HD gene expression
study with the same direction in expression change [10].
However, Cai et al. [11] showed that little preservation
occurs in mean expression levels between the brain and
blood. It is however possible that signals are preserved
at levels beyond gene expression. For instance, Chuang
et al. pointed out that subnetwork markers in a protein-
network-based approach were significantly more repro-
ducible than individual gene markers in two different
cancer cohorts [12].
The most robust HD disease signature based on tran-
scriptomics data to be used for drug development and
disease progression biomarkers should be present in both
blood and brain [13, 14]. Because the blood signature is
derived from non-neuronal tissue and the brain signature
is masked by non-HD related processes such as hypoxia,
the shared signature is likely the most informative from
a mechanistic and therapeutic point of view. We used a
systems biology approach that combines Weighted Gene
Co-expression Network Analysis (WGCNA) [15, 16]
and literature mining technology [17, 18] to assess the
similarity between brain and blood tissue using previ-
ously published gene expression studies in brain and blood
[5, 10]. We prioritized signatures that were shared
between blood and brain tissue at a systems level, based
on mechanisms that involve multiple genes and proteins.
In general, genes that are part of the same mechanism,
exhibit similar expression changes. At the mechanis-
tic level we can compare signature signals from post-
mortem HD brain tissue and blood to provide novel
biomarkers that can be measured in blood to mon-
itor the brain pathology in living patients. Such an
approach offers many advantages and can also be use-
ful for other neurodegenerative disorders. Apart from the
non-invasive nature of blood sampling, it is also cost
effective and widely available. This can lead to the devel-




The blood dataset used in this work consists of tran-
scriptomics data obtained by next generation sequenc-
ing (NGS) from whole blood. The dataset consists of 33
controls, 27 presymptomatic mutation carriers and 64
symptomatic mutation carriers. The phenotypes associ-
ated with this dataset that we used in this analysis were
carrier status, CAG repeat length, and two clinical scores
namely motor score and Total Functional Capacity (TFC)
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score. The TFC score is inversely correlated to the motor
score and the CAG repeat, and it reflects the disease
severity with lower numbers indicating higher severity of
the disease. The carrier status was assigned ’0’ for con-
trols and ’1’ for HD carriers. The CAG repeat values
ranged between 17 and 53, covering both controls and HD
samples. The motor score of the control subjects ranged
between 0 and 11 and between 0 and 107 for the HD
subjects. The TFC score for the control subjects ranged
between 11 and 13 and for the HD subjects between 0
and 13.
We used the processed blood data set that is publicly
available in the NCBI Gene Expression Omnibus (GEO)
database under accession number GSE51799. Details for
the dataset can be found in the original publication [10].
We removed the presymptomatic samples from the
blood samples because there were only 3 presymptomatic
samples in the brain study. We also removed transcripts
with low tag count (less than 94). The dataset was nor-
malized using the calcNormFactors (TMMmethod) from
the edgeR bioconductor package for RNA-Seq [19]. In
addition, the dataset was transformed using the method
described in [20].
Brain dataset
The HD human brain data used in this analysis were
obtained from the public repository NCBI Gene Expres-
sion Omnibus, entry GSE3790. The data set was orig-
inally created and analyzed by Hodges et al. [5]. It
contains 44 HD gene positive cases and 36 age and sex
matched controls. They analyzed three different brain
regions, caudate nucleus, frontal cortex (BA4 and BA9
regions) and cerebellum, with an Affymetrix Microarray
GeneChip (Human Genome U133A and U133B). In addi-
tion, they classified the HD cases based on Vonsattel grade
of disease pathology (scale = 0 –4). We used the pro-
cessed data from the Human Genome array U133A to
construct the WGCNA network. The dataset was log2
transformed.
Application of weighted gene co-expression network
analysis (WGCNA)
The transformed blood and brain datasets were used
to construct the weighted gene co-expression networks.
We used the original WGCNA algorithm as described
in [15].
The parameters were chosen based on the assumption
of a scale-free topology of the co-expression network,
according to WGCNA guidelines, and also in order to
make modules from each network of comparable sizes.
Other parameters followed default settings that are based
on earlier investigations of the WGCNA method by
Horvath et al. [15, 16]. The soft threshold for each net-
work was: caudate: 9, BA4: 3, BA9: 5, cerebellum: 5, blood:
9. The parameter minModuleSize was assigned to 15 for
all networks. We performed module identification using
the dynamic tree cut algorithm [21]. The parameters for
the module identification were chosen as to avoid creat-
ing many large modules. We chose method = “hybrid”
for all networks, deepSplit = 2 for all brain networks and
deepSplit = 0 for the blood network. Changing the deep-
Split parameter that results in larger or smaller modules
appeared to have minimal effect on the composition of
genes and annotations of modules (data not shown). The
parameter cutHeight was chosen as cutHeight = 0.999 for
all brain networks and cutHeight = 0.995 for the blood
network. For the blood network we chose MEDissThres
= 0.30 for merging modules whose expression profile was
similar. In order to keep the module sizes of the brain net-
works comparable to the blood network the MEDissThres
parameter for all four brain networks was chosen to be
MEDissThres = 0.0001. In total we identified 34 modules
in the blood dataset consisting of a median of 66 genes
(mean:233). In the brain dataset we identified in total 55
modules in the caudate nucleus, 67 in BA4, 118 in BA9 and
81 in cerebellum. Details on the association of modules
per network with the disease phenotypes can be found in
Additional file 1.
Module size per network in the brain datasets were for
the caudate median: 105.0, mean: 335, for the cerebel-
lum median: 75, mean: 275.1, for the BA4 median: 67,
mean: 332.6 and for the BA9 mean: 51.5, median: 188.
The association of modules with the disease phenotypes
was performedwith an implementation of the R’s standard
cor function in the WGCNA package. The correlation
method that was used was Pearson correlation.
Concept profile analysis
We performed Concept profile analysis (CPA) which was
previously described in [17, 18]. In short, CPA is based
on comparing concept profiles that were mined from
the literature. To construct a concept profile, PubMed
abstracts are indexed by Peregrine (https://trac.nbic.nl/
data-mining/), using a thesaurus of biomedical and chem-
ical concepts that has been prepared in-house for text
mining [22, 23]. For every concept in the thesaurus that
is associated to at least five PubMed records, a concept
profile is created. A concept profile is a vector contain-
ing all concepts related to the main concept (by direct
co-occurrence in PubMed abstracts). Each relation is
weighted by the symmetric uncertainty coefficient. Con-
cept profiles are matched with each other to identify
similarities via their shared concepts (indirect relations).
Any distance measure can be used for this matching
such as the mutual information, inner product, cosine,
angle, Euclidean distance or Pearson’s correlation. The
CPA Web Services that we used for our analysis use the
inner product measure.
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Module annotation - parameters and semantic types
The modules were annotated with concepts of a certain
semantic type using the Taverna [24, 25] workflow which
is publicly available from the myExperiment repository
http://www.myexperiment.org/workflows/3921.html.
This workflow orchestrates a series of CPA web services
for module annotation which use literature that was
mined up to July 2012.We used a selection of 4 predefined
concept sets from our local database of concept profiles.
A concept set is a collection of concept profiles related to
a particular semantic type (e.g. biological processes). The
concept sets that we used in our analysis were: biological
processes (ID:5), cellular component (ID:3), molecular
function(ID:4) and disease or syndrome (ID:82). The
first three concepts sets are based on the Gene Ontology
(GO). Gene Ontology (GO) terms are often given as
words or phrases that are infrequently found in normal
texts. To still provide broad coverage of GO terms, we
previously developed a procedure specifically for GO
[17]. In short, the GO concept profiles were created based
on the literature (PubMed identifiers) provided in the GO
database itself. That includes literature based on all gene-
GO term associations and GO-terms without an explicit
association with genes (version 2012-07-14, direct down-
load link: http://archive.geneontology.org/lite/2012-07-
14/go_20120714-assocdb.rdf-xml.gz). The disease or
syndrome concept set provides information about dis-
eases or syndromes that currently exist in the UMLS [26]
and OMIM databases [27], by using information from the
complete literature. The top 20 annotations (based on the
sum of their similarity scores with all of the genes in a
module) from each concept set was used to annotate each
module. The annotation of modules was performed by
matching the concept profiles of the genes in the module
with each of the concept sets. To subsequently define the
similarity between a pair of modules (one from brain and
one from blood), we counted the number of overlapping
annotations between each module pair.
Randomization approach and significance of the modules
The following algorithm was applied separately for each
of the comparisons between the datasets and for each
semantic annotation category separately. Suppose we have
identified n modules A1,A2, . . . ,An in blood and m mod-
ules B1,B2, . . . ,Bm in one of the brain regions. We use
CPA to annotate each module and compute similarity
scores Sij for all pairs (Ai,Bj), based on the number
of overlapping annotations. To assess the significance
of these similarity scores, we use a permutation-based
approach as follows. For k = 1, 2, . . . 100, we gen-
erate sets of random modules A1k ,A2k , . . . ,Ank and
B1k ,B2k , . . . ,Bmk of the same size as the original modules
A1,A2, . . . ,An and B1,B2, . . . ,Bm. We compute similarity
scores Sijk l for each pair (Aik ,Bjl). On the basis of these
10,000 permutation-scores, we use Westfall and Young’s
minP method [28] to compute the significance of each
module pair (Ai,Bj). Note that this method aims to control
the familywise error rate (FWER) by adjusting for the fact
that we make n × m comparisons. As explained in [29],
the fact that the scores are discrete causes the Westfall-
Youngmethod to be conservative. To counter this, we have
decided to set the significance level at 10 %. We do point
out that to reach this level of significance, the observed
similarity score should be the most extreme among all
permutations. Also, driven by biological interpretation of
module pairs that are associated with sexual differentia-
tion that had a large number of overlapping annotations
and number of overlapping genes we decided to include
module pairs up to a significance level of 50 %. Thesemod-
ule pairs are indicated in Additional file 2 with dashed
lines.
Results
Workflow to identify HDmodules in blood and common
functional signatures between blood and brain
In order to identify common Huntington disease-specific
signatures in brain and blood, we created groups of
co-expressed genes (modules) using weighted gene co-
expression network analysis (WGCNA). We first applied
WGCNA to the blood and brain dataset and identified
modules that were associated with the disease phenotype.
We then used Concept Profile Analysis (CPA) technol-
ogy to annotate each module separately with different
semantic annotation categories and assess the similarity
between the different networks (blood versus the four
brain regions) based on the overlap of the module anno-
tations (Fig. 1). The annotations were based on four
semantic categories: biological processes, cellular compo-
nent, molecular function and disease or syndrome. The
categories correspond to the main branches in the gene
ontology as a natural way to distinguish between differ-
ent views on biological function [30]. The gene enrich-
ment analysis that CPA performs differs from the classical
GO gene enrichment analysis because CPA annotates
genes by mining biomedical literature, allowing the iden-
tification of more specific GO categories as previously
demonstrated in [30], while the GO annotations are man-
ually curated.
Disease signatures identified in the blood data set
For our functional analysis of HD signals in blood data, we
used our blood network modules that were identified by
WGCNA. We identified in total 8 modules that were cor-
related with the disease phenotype from a total number
of 34 modules (Fig. 2). Each module was annotated using
CPA and the most representative annotations comprised
the signature of that particular module. The extended list
of the bloodmodules and their associated annotations can
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Fig. 1Workflow for the identification of common signatures between
blood and brain tissue. The blood and brain datasets are transformed
into gene co-expression networks using Weighted Gene Co-
expression Network Analysis (WGCNA). The networks are represented
by modules, groups of highly co-expressed genes. Modules
significantly correlated with HD are identified. The modules are
annotated using Concept Profile Analysis (CPA), using four semantic
annotation categories i.e. Biological Processes, Cellular Component,
Molecular Function and Disease or Syndrome. Next, the similarity
between the annotated modules from each network is assessed (for
each semantic annotation category) based on the total number of
overlapping annotations between each blood-brain module pair
(pairwise matching). The significance of each module pair is assessed
by repeating the entire analysis using randomly composed modules
of the same gene size as the original ones. The random distribution
was used to assign a significance value for each module pair. At the
bottom of the figure, the module pairs that cross our threshold
(P value < 0.05) which compose our two blood-brain signatures
be found in Additional file 3 and more detailed informa-
tion about gene composition and annotations per module
in Additional files 4 and 5. Here, we describe the top 5
signatures.
• Immune response (violet module) was positively
correlated with TFC score and negatively correlated
with CAG repeat length and motor score.
Inflammation can be detected in monocytes from
presymptomatic patients [31] and a gene expression
inflammation signature was also reported by
Mastrokolias et al. [10].
• Cell cycle and protein transport (green module) were
positively correlated with motor score and CAG
repeat. Recent studies in mouse models of HD
suggest that abnormalities in the cell cycle may
contribute to the HD pathogenesis [32, 33].
• Sphingolipid biosynthetic process (thistle2 module)
was positively correlated with TFC score and
negatively correlated with motor score. Sphingolipids
are essential for brain function and recently they were
reported as candidate biomarkers in Alzheimer’s
disease based on evidence that sphinglolipid levels are
associated with cerebrospinal fluid (CSF) amyloid
β42 concentration [34]. In addition, an independent
study reported sphingolipids being associated with
restoration of motor behavior in HD mice [35].
• Cell signaling and synaptic transmission (orangered4
module) were positively correlated with motor score
and negatively with TFC score. The HAP1 gene is
included in this module that encodes for the
huntingtin associated protein 1 which directly binds
to huntingtin [36].
• Phospholipid transport and dephosphorylation, and
RNA splicing (salmon4 module) were positively
correlated with CAG repeat and carrier status.
Phospholipids have been proposed as targets for
therapeutic intervention in HD, because of the
finding that mutant huntingtin is able to interact with
phospholipids in membranes [37], with different
affinity and preference for specific phospholipids,
depending on the polyglutamine expansion [38].
The number of genes that were part of the 8 modules
that were correlated with HD accounted for 8.72 % of
the total number of genes detected in the blood exper-
iment. In contrast, only 1.03 % of genes was identified
as differentially expressed using classical differential gene
expression (DGE) analysis [10]. Investigating this further,
we find an overlap of twelve genes between the differ-
entially expressed genes from the DGE analysis and the
genes that were part of the significantly correlated mod-
ules. Ten out of the 62 genes from the inflammation
module overlapped with this common set of 12 genes,
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Fig. 2 Significantly correlated blood modules with 4 different disease phenotypes. Each module was assigned a different color name, cf standard
WGCNA. Significant modules were identified by correlating the module eigengenes (first principle component of the summary of gene expression
profiles within a module) to the disease phenotypes, i.e. carrier status, CAG repeat, motor score and Total Functional Capacity (TFC) score, a measure
for disease severity. On the y-axis: the top 8 correlated modules, x-axis: the disease phenotypes. The numbers represent the Pvalue for the
correlation per module. Green: negative correlation, red: positive correlation. The intensity of the color depicts the strength of the correlation
suggesting a strong disease effect on the expression of
these genes.
WGCNA in the brain dataset
We also applied WGCNA to the four brain regions sep-
arately to identify modules that are correlated with the
disease phenotype. WGCNA has been applied before in
the same brain dataset [39–41] but we had to reanalyze
this data to obtain module sizes that were comparable
with the modules from the blood dataset.
We found the highest number of modules associated
with the HD phenotype in the caudate nucleus (37 mod-
ules). Cerebellum and BA4 follow with 29 and 23 modules
respectively (Additional files 1 and 6). BA9 exhibited poor
association with HD since none of the BA9 modules were
significantly correlated with the disease state. However,
a large number of modules exhibited a strong associa-
tion with the disease staging phenotype (Additional files 1
and 6).
Because the semantic annotations of the modules from
each brain network can be relevant for future research, we
report here the processes that were prominently present
in all brain regions: immune response, chromatin remod-
eling, histone modification, cell-cycle, myelination and
cell differentiation (oligodendrocyte, axon and Schwann
cells), synaptic activity, protein transport, nuclear activity,
protein kinase activity and RNA splicing.
Our analysis confirmed the neurodegeneration pat-
tern in HD as previously described in [5], and was also
described by the WGCNA analysis in [39]. Overall the
functional comparison of our semantic annotations with
the results from [39] showed a high degree of similar-
ity. For instance, RNA splicing, protein transport, protein
modification, immune response, chromatin organization
and DNA damage were identified by both analyses.
Association of modules between different tissues - module
pairing
In order to identify signatures that represent mechanisms
that are common inHDblood and brain tissue we used the
annotated modules from each network (blood, caudate
nucleus, cerebellum, BA9 and BA4) to compare them pair-
wise and calculate the number of overlapping annotations
for each blood-brain pair for the four semantic annotation
categories separately (Fig. 1). Only significant blood-brain
pairs were considered for further analysis. The signifi-
cance of each module pair was assessed by repeating the
entire analysis using randomly composed modules of the
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same number of genes, which we annotated using the
same four annotation categories. A significance value was
assigned to each module pair using a random distribution.
The similarity between blood and each brain region was
assessed by the total number of significant module pairs
per semantic annotation category. Caudate nucleus and
BA4 exhibited the highest similarity with blood (Fig. 3),
in all semantic annotation categories. BA9 exhibited an
intermediate similarity, while cerebellum had the least
similarity with only one significant module pair in the
cellular component annotation category. None of the
brain regions exhibited similarity with blood based on
the molecular function annotation category.
Common signatures shared by blood and brain
We define a blood-brain module pair to represent a com-
mon disease signature when it meets the following crite-
ria: 1: significance value of the blood-brain module pairs,
2: each module separately is associated with at least one
of the HD phenotypes as identified by WGCNA. We
named the signatures according to their most representa-
tive annotation. From the total number of associatedmod-
ules between blood and brain (Fig. 3) we identified in total
two common disease signatures based on these criteria
(Fig. 4; Additional files 7 and 8). We named the signatures
according to their most representative annotation.
Signature 1. The immune response signature was shared
between blood and caudate (Fig. 4a). This signature was
identified based on the biological processes annotation
category. Common annotations included major histo-
compatibility complex location, lymphocyte activation,
cytokine activity, T cell activation and adaptive immune
response. The caudate nucleus module consisted mainly
of HLA genes of the major histocompatibility complex
class I (A, B, C, F, G).
Signature 2. The Spinocerebellar ataxias (SCAs) signa-
ture was shared between blood and the caudate nucleus
(2 modules) (Fig. 4b), based on the disease or syndrome
annotation category. The link that was shared between
one of the caudate nucleus modules (saddlebrown; indi-
cated with a dashed line) and blood achievedmarginal sig-
nificance, with FWER of 30 %. The annotations that were
common in this signature were multiple forms of SCAs,
from both the polyglutamine and non-polyglutamine
repeat disease class (SCA types 1,2,3,6,7,8,10,12 and 17).
Comparison with preservation and gene wise overlap
To investigate how our method compares to other meth-
ods, we compared the results of the blood - caudate
nucleus semantic analysis to gene overlap counts between
blood and caudate nucleus modules, and to the preser-
vation statistics method from the WGCNA itself (Fig. 5).
The gene overlap analysis identified in total 3 blood mod-
ules exhibiting significant gene overlap with the caudate
nucleus modules, of which none was significantly corre-
lated with the disease phenotype. The preservation from
the WGCNA identified in total 6 blood modules that
were preserved in the caudate nucleus (Zcore values:
2 < Zcore < 10) of which two were significantly cor-
related with HD (blue and salmon4). Our methodology,
using CPA, identified in total 5 blood modules associ-
ated with the caudate nucleus modules; three of which
were significantly correlated with the disease (violet,
plum1, orangered4) (Fig. 5). This shows that our analy-
sis is comparable to other well-established methods and
can produce results that are rather complementary for
Fig. 3 Semantic comparison between the modules of four brain regions and blood. The total number of blood-brain pairs per semantic type above
our significance threshold (FWER <= 10 %) is depicted by each color bar. Blood exhibits the highest similarity with both the caudate and BA4. BA9
and cerebellum follow with slightly higher scores for BA9
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Fig. 4 The two blood brain signatures identified by our analysis. The yellow circles indicate caudate nucleus modules and red color indicates blood
modules. The line between two modules indicate a significant link (blood-brain pair) between modules (FWER <= 10 %). Dashed line indicates a
module pair with marginal significance (FWER < 50 %). Different color lines indicate an association based on each semantic annotation. Black:
Biological processes, red: Disease or Syndrome
the identification of common disease signatures between
blood and brain.
Discussion
In this paper we usedWGCNA and literature information
to identify modules in blood that are associated with the
HD phenotype and to identify disease signatures that are
shared between blood and brain. To our knowledge, this is
the first time that the similarity between blood and brain
tissue was successfully assessed based on a combination of
WGCNA and literature information. WGCNA was used
in order to group genes of the same tissue that are co-
expressed (modules), while literature information (CPA)
was used to annotate and evaluate the similarity between
modules from different tissues at a functional level.
In summary, we identified 8 HD-specific modules in
blood and two distinct signatures that are shared between
blood and brain. The HD-specific modules in blood
were associated with immune response, sphingolipid
biosynthetic process, lipid transport, cell cycle, protein
modification, spliceosome, RNA splicing, vesicle trans-
port, cell signaling and synaptic transmission. This anal-
ysis points to mechanisms that are affected in HD. Some
were already known to be implicated in the brain pathol-
ogy, but their role in blood has not been elucidated yet
[31, 32, 42, 43].
The scarcity of HD brain tissue has driven research
to use blood to identify biomarkers that can be used
to study disease state and disease progression that are
most clearly observed in the brain. In previous studies the
similarity between blood and brain was assessed based
on the conservation of gene expression patterns only
[8–10]. Such assessments are usually very difficult,
because blood and brain are two inherently different tis-
sues composed of very different cell types. Nevertheless,
in our study, we discovered signatures that are based
on a functional similarity between blood and brain. We
argue that the same function may partially be executed
Fig. 5 Comparison of the results between CPA in four semantic annotation categories, gene overlap counts, and module preservation. For the
preservation analysis, we used the Z-summary metric, a composite preservation measure that identifies modules that are preserved in other
networks based on their connectivity and density statistics. Significant module pairs for the gene wise overlap were computed the same way as for
the annotation overlap using CPA (Methods). The figure shows the blood modules that were significantly associated with the caudate nucleus
network. Each different method is depicted with a green diamond. The oval shapes with thick black lines represent modules significantly correlated
with the disease phenotype. Only one module is shared by all three approaches (lightcyan1), which is not significantly correlated with the disease
phenotype. The overall overlap between the methods is small
Mina et al. Orphanet Journal of Rare Diseases  (2016) 11:97 Page 9 of 13
by different gene products in different cell types, also
considering that our current knowledge may have dif-
ferent gaps across cell types. At the functional level the
active units are not merely the genes, but cells and organs.
Cells of different types that play a role in the execu-
tion of a biological function express different genes that
are thus associated with that function. It is therefore a
fair assumption that when comparing between cell types,
we should look beyond the level of individual genes.
For instance, microglia and macrophages both partici-
pate actively in the immune response but different sets
of genes are expressed in microglia or macrophages [44].
Another example where two different gene products carry
out the same function is hemoglobin andmyoglobin. Both
genes are associated with transport of oxygen, but one
is expressed in red blood cells and the other in mus-
cle [45–47]. Therefore, signatures based on co-expression
and functional annotation are more likely to represent
disease-specific mechanisms. We speculate that a com-
mon signature at the functional level is more robust,
which makes it attractive to monitor disease progression
or the efficacy of a particular treatment. The blood-brain
signature allows us to focus on a specific part of the blood
signal to monitor the HD-affected brain.
Our findings suggest that mechanisms associated with
inflammatory response and SCA are important mecha-
nisms that are shared between blood and brain in HD
(Fig. 4). The inflammation response may be an impor-
tant component of HD pathology that contributes to the
neuropathological damage. This finding supports previ-
ous detection of abnormal activation of immune response
in HD patients [31]. In addition, this signature links the
well-established neuroinflammation signature in brain to
a parallel inflammatory response in blood, triggered upon
expression of the mutant huntingtin. The same signa-
ture was also identified by Horvath and colleagues in
their study of the preservation of brain modules in two
large blood cohorts of healthy individuals [11]. Although
they were unable to identify full module preservation,
they found that a subset of the genes that was preserved
was functionally enriched in, among others, infectious
disease and infection mechanisms. Both analyses point
to an immune response mechanism as a shared chan-
nel between blood and brain. Although the mechanisms
preserved in those datasets came only from healthy indi-
viduals, we conclude that this preserved signal is also
specific for HD.
In addition, we showed that blood exhibits similari-
ties with brain based on different criteria (Fig. 3). These
criteria reflect similarities on a functional level i.e. bio-
logical processes, cellular component, molecular function,
and functions associated with the same disease or syn-
drome. The disease or syndrome annotation led us to
the identification of the SCA signature (Fig. 4b). The
association of blood modules with brain disorders is by
itself an interesting topic for further research. A signature
based on commonality in disease or syndrome annota-
tions would have been difficult to identify by approaches
that only focus on gene expression or traditional annota-
tion schemes (e.g. GO based annotation). Genes that were
part of this signature on the brain side were the TCF4,
ATN1, PPP2R2B, ATXN10 and ATXN3, which are associ-
ated with neurodegenerative and developmental disorders
such as Pitt-Hopkins Syndrome [48], Dentatorubral pal-
lidoluysian atrophy [49], SCA12 [50], SCA10 [51] and
SCA3 [52]. On the blood side of this signature were
among others the PPP2R2B gene associated with SCA12,
CAPNS2, which was recently found to play a benefi-
cial role against polyglutamine toxicity [53], and SETBP1
which is associated with the Schinzel-Giedion syndrome
[54, 55].
The comparison of the results of our methodology
with those obtained by the preservation statistics from
WGCNA, and those from assessing the gene overlap
between blood and brain, shows that the three method-
ologies are complementary. The overlap between the
three methods was very small (Fig. 5) indicating that they
identify similarities based on different criteria. In fact,
the signature that was identified by all methods was not
associated with the HD phenotype, but with sexual dif-
ferentiation. The modules in this signature are strongly
co-expressed and composed mainly of genes expressed on
the X and Y chromosome. The identification of this signa-
ture served also as a control for testing the validity of each
method. Depending on the hypothesis that drives one’s
analysis, one or a combination of these methods could be
used. Our method has the advantage that for identifying
similarity we solely look at similarity at a functional level,
i.e. without bias in terms of overlapping genes or similarity
in expression patterns between the two tissues.
Additional disease relevant signatures
In addition to the aforementioned signatures that were
selected by the most strict criteria, we identified two addi-
tional module pairs based on less stringent criteria that
we considered interesting for HD. The first criterion that
we used in this analysis was that a module pair needed to
achieve a significance level of 10 % of FWER. As explained
in the Methods section, we define a “gray” significance
level of up to 50 %, based on the significance levels that
we observed for the sexual differentiation modules that
served as internal control. The second criterion was that
each module in particular needed to be significantly cor-
related (P value < 0.05) with at least one of the disease
phenotypes. Detailed information about these common
signatures can be found in Additional files 9 and 10.
The synapse signature was shared between blood and
the caudate nucleus based on the cellular component
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annotation category (Additional file 2A). The caudate
nucleus module (indicated with a dashed circle) was
marginally associated with the disease staging phenotype
(P value = 0.074; Additional file 1) while the blood mod-
ule was associated with motor and TFC score. Common
annotations in this signature were associated with synapse
activity and dendrites. Albeit the absence of cells with
synapses in the blood, the annotation of the blood module
with concepts like “synapse” hints at the presence of gene
products with a function in the neuronal synapse and an
alternative function in the blood, which may be used as
a surrogate marker for the effect of disease on neuronal
transmission.
The genes that contribute themost to the synaptic activ-
ity annotation are NOS1, HAP1, GRIK2, HTR6. Literature
supports that at least three of them are directly implicated
in HD [36, 56, 57]. In fact, HAP1 was one of the first pro-
teins that were described to interact with huntingtin [36].
The genes encode ubiquitously expressed proteins with a
known function in brain, but their role in blood remains
elusive. GRIK2 was proposed as a candidate biomarker
in Chronic Fatigue Syndrome (CFS) after it was detected
in the peripheral blood of CFS patients as differentially
expressed [58]. NOS1 was also associated in studies as
being able to regulate blood pressure [59].
In addition, 7 out of 18 members of this module
(MTRNR2L1, LAPTM5, QRICH1, MOAP1, AKR1B1,
NOS1, ZNF260) were found to be indirectly associated
with huntingtin through the interaction with the UBC
protein that is known to interact with huntingtin [60–65].
Finally, cell-cell signaling (NOS1, HAP1, GRIK2, HTR6),
ion transport (HAP1, UNC80, KCNAB1), cell death,
and apoptosis (LAPTM5, MTRNR2L1, MOAP1, QRICH1)
were secondary annotations associated with this blood
module. The majority of the genes in this module encode
ubiquitously expressed proteins that are likely to have a
catalytic role in the HD blood, similar to their effect in
brain. The synaptic signature can potentially be of great
value for monitoring synaptic activity in brain bymonitor-
ing these genes in HD blood.
The vesicle trafficking and protein transport signature
was shared between blood and BA4 based on the cellu-
lar component annotation category (Additional file 2B).
In this signature, the blood module was marginally associ-
ated with the CAG repeat phenotype and also this module
pair was identified with a significance level of 50 % of
FWER. The annotations that were shared in this signa-
ture were related to endosomes, trans-golgi network and
clathrins. This signature was also identified by Horvath et
al. as a preserved mechanism between blood and brain in
healthy individuals [11].
Both the synaptic activity and vesicle transport signa-
tures have been long implicated in HD. Huntingtin is
expressed in the cytoplasm where it directly interacts with
a number of proteins involved in synaptic activity and
vesicle transport [66]. In addition, huntingtin has been
previously described as a protein that acts as a mediator
in information trafficking between different cell compart-
ments by interacting with other proteins [67]. Recent
evidence suggests that synapse loss and other features
of the disease that involve the CNS can be treated by
targeting organs outside the CNS [68]. The blood mod-
ules involved in these signatures that link the blood with
the brain pathology could become subject for further
research to confirm whether symptoms of the disease can
be treated by targeting factors that associate with these
modules [68].
Although the blood-brain signatures that we identi-
fied are promising, there are certain limitations in our
methodology that can be improved in follow up stud-
ies. Considering that similarity was assessed by overlap
in annotations, future studies can extend the power of
the method by using the hierarchy of an ontology to
assign a score to annotations that are subclasses of the
same function. Furthermore, the results from the compu-
tational analysis can be corroborated by further validation
on additional data and by new experiments in the labo-
ratory. The genetic predictability of HD allows for testing
those signatures in carriers of the gene mutation both in
mouse and humans, even before the first symptoms arise.
We are currently investigating the analysis of data from
human blood samples that were collected from the same
subjects, but 4 years later as an accurate way of determin-
ing whether these signatures have changed over the time
andwhether they correlate with the progression of the dis-
ease. Testing these signatures in mouse models of HD to
follow the efficiency of novel disease treatment strategies
would also be beneficial for using and optimizing blood as
a diagnostic and monitoring tool.
Conclusion
In summary, we present functional HD-specific co-
expression signatures in blood samples that link specific
processes, measured in blood, to the pathology of HD.
These signatures can be used to further study changes in
blood and identify biomarkers that can track disease stage
and progression. In addition, we identified two common
signatures that are shared between blood and multiple
brain regions in Huntington’s Disease. These signatures
are likely an indication of disease changes that occur in
parallel between these two tissues. These results are a step
towards using blood as a surrogate to study the pathol-
ogy in brain in HD, by using only that part of the signal
that we can link to processes known to be in common and
associated with the disease. Having a peripheral measure
to monitor brain pathology opens new gateways to have a
more in-depth understanding at several time points of dis-
ease progression and monitor the efficacy of treatments
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in a non-invasive manner. Our approach is applicable to
other disorders where it is not feasible to obtain data from
the most affected tissues.
Additional files
Additional file 1: Significantly correlated modules in brain. This file
contains the modules from each brain region (caudate, BA4, BA9 and
cerebellum) that were associated with the disease phenotype. The
numbers (P value) indicate the correlation of each module with the disease
phenotype. Green: negative correlation, red: positive correlation. The
intensity of the color depicts the strength of the correlation. (PDF 1341 kb)
Additional file 2: Additional disease signatures. This file contains the
additional disease signatures that were identified with less stringent
statistical criteria. The yellow circle indicates a caudate nucleus module,
bluegrey circle indicates a module from the BA4 brain region and red color
indicates blood modules. The line between two modules indicates a
significant link (blood-brain pair) between modules (FWER <= 10 %).
Dashed line indicates a module pair with marginal significance
(FWER < 50 %) while dashed circles indicate modules with marginal
significance with the disease phenotype. The green line between module
pairs defines an association based on cellular component. (PNG 66.6 kb)
Additional file 3: Modules in blood significantly correlated with HD. This
file contains the 8 modules that were identified in blood as being
correlated to the HD phenotype. The file describes each module according
to the most representative annotations per semantic category (biological
processes, cellular component, molecular function, disease or syndrome).
(DOC 16.5 kb)
Additional file 4: Annotations of blood modules associated with HD. In
this file we include detailed information about the annotations per
semantic type of each module in blood that is associated with HD.
(XLS 37 kb)
Additional file 5: Gene identifiers of blood modules associated with HD.
In this file we include the gene identifiers that constitute each module in
blood that is associated with HD. (XLS 84 kb)
Additional file 6: Association of the brain regions with the disease
phenotype. This file describes the total number of modules, per brain
region, that are associated with the the two HD phenotypes; the disease
state (HD or control) and disease staging (grade 0 - 5) as that was resulted
by the WGCNA. (PNG 54.9 kb)
Additional file 7: Immune response signature. In this file we include
detailed information about the immune response signature, including the
annotations and gene identifiers of each module that participates in this
signature. (XLS 15 kb)
Additional file 8: SCA signature. In this file we include detailed
information about the SCA signature, including the annotations and gene
identifiers of each module that participates in this signature. (XLS 25 kb)
Additional file 9: Synapse signature. In this file we include detailed
information about the synapse signature, including the annotations and
gene identifiers of each module that participates in this signature.
(XLS 12.5 kb)
Additional file 10: Vesicle transport signature. In this file we include
detailed information about the vesicle transport signature, including the
annotations and gene identifiers of each module that participates in this
signature. (XLS 13 kb)
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